March 2016 News Recap

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

A systematic review shows that well-designed randomized clinical trials are necessary to optimize treatment strategies with tislelizumab in lung cancer.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

April 21st 2025

TTFields Therapy Earns EU Approval in Metastatic Non–Small Cell Lung Cancer

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Data from the phase 3 LUNAR trial support the Conformité Européenne Mark for tumor treating fields in metastatic non–small cell lung cancer.

Cristiane Decat Bergerot, PhD

April 14th 2025

Ivonescimab/Chemo Prolongs PFS in 1L Advanced Squamous NSCLC

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Tim Cortese

FDA Grants EvoLiver Biopsy Test Breakthrough Device Designation for HCC

The phase 3 HARMONi-6 trial found invonescimab plus chemotherapy improved PFS vs tislelizumab plus chemotherapy in squamous NSCLC.

MEV01 trial results show that the test achieved an 86% early-stage sensitivity and 88% specificity in surveillance of HCC among patients with cirrhosis.

Roman Fabbricatore

Tislelizumab Significantly Boosts Survival in Lung Cancer Trials

MEV01 trial results show that the test achieved an 86% early-stage sensitivity and 88% specificity in surveillance of HCC among patients with cirrhosis.

Related Content

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

A systematic review shows that well-designed randomized clinical trials are necessary to optimize treatment strategies with tislelizumab in lung cancer.

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

April 21st 2025

TTFields Therapy Earns EU Approval in Metastatic Non–Small Cell Lung Cancer

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Data from the phase 3 LUNAR trial support the Conformité Européenne Mark for tumor treating fields in metastatic non–small cell lung cancer.

Cristiane Decat Bergerot, PhD

April 14th 2025

Ivonescimab/Chemo Prolongs PFS in 1L Advanced Squamous NSCLC

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Tim Cortese

FDA Grants EvoLiver Biopsy Test Breakthrough Device Designation for HCC

The phase 3 HARMONi-6 trial found invonescimab plus chemotherapy improved PFS vs tislelizumab plus chemotherapy in squamous NSCLC.

Roman Fabbricatore